# IMMUNOSENS Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunosens-co

- Industry: Medical Devices & Equipment
- Headquarters: Suita-shi, Japan
- Website: https://immunosens.com
- Total disclosed funding: $8.1M
- Latest round: Series B (Jul 31, 2023)
- Investors on record: 11

## About

Based in Japan, IMMUNOSENS Co. Ltd. focuses on manufacturing advanced diagnostic tools and immunoassay technologies to enhance disease detection and monitoring through innovative solutions.Founded in 2018 and headquartered in Suita-shi, Japan, IMMUNOSENS Co. Ltd. develops diagnostic tools that support healthcare professionals in disease management. In November 2025, IMMUNOSENS Co. Ltd. raised an undisclosed amount ?in?venture funding ?from new investors Chushin Venture Capital and MIRAIDOOR, Kansai Mirai Bank and Sumitomo Mitsui Banking Corporation, with participation from returning investors Global Brain, Kiyo Capital Management and SMBC Venture Capital. The round was part of equity and debt funding.

Immunosens specializes in developing and manufacturing advanced diagnostic tools and immunoassay technologies aimed at enhancing disease detection and monitoring. Their core product offerings include innovative assays that leverage proprietary technologies to deliver precise and reliable results for various conditions, including autoimmune disorders and infectious diseases. These products aim to provide healthcare professionals with critical insights that aid in patient management, ultimately improving clinical outcomes. Immunosens serves a diverse client base comprising hospitals, laboratories, and research institutions across Europe and North America, offering solutions tailored to the specific needs of each market while meeting stringent regulatory standards.Immunosens generates revenue through a structured model that includes both direct sales and partnerships with healthcare providers and research institutions. Their flagship products are marketed through B2B channels, where healthcare entities procure diagnostic assays as part of their laboratory services. Transactions are facilitated through established frameworks, including volume-based pricing agreements and subscription models for ongoing supply of testing kits and reagents. Long-term contracts with customers ensure a steady revenue stream for the company, reflecting the value provided in terms of accuracy and reliability for diagnostic workflows.

The company plans to use the November 2025 funding to advance the social implementation and business expansion of the ultra-compact, POCT platform.

## Funding rounds

- Series B, Jul 31, 2023, $3.9M — Global Brain, Shimadzu Corporation
- Series B, Feb 2, 2023, $1.3M — SMBC Venture Capital, Global Brain, Senshu Ikeda Capital, TOPPAN Holdings, Resona Capital, JMTC Capital, Mitsubishi Materials Corporation, Kiyo Capital Management, Sumitomo Pharma Animal Health Co., Ltd.
- Series A, Mar 30, 2021, $1.2M — Osaka University Venture Capital
- Series A, Dec 2, 2019, $1.1M — Osaka University Venture Capital
- Seed, Apr 24, 2018, $0.6M — Osaka University Venture Capital

## Investors

- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Seed, Series A
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B
- Global Brain (https://capitalatlas.ai/funds/global-brain) — Series B
- Senshu Ikeda Capital (https://capitalatlas.ai/funds/senshu-ikeda-capital) — Series B
- TOPPAN Holdings — Series B
- Resona Capital (https://capitalatlas.ai/funds/resona-capital) — Series B
- JMTC Capital (https://capitalatlas.ai/funds/jmtc-capital) — Series B
- Mitsubishi Materials Corporation — Series B
- Kiyo Capital Management (https://capitalatlas.ai/funds/kiyo-capital-management) — Series B
- Sumitomo Pharma Animal Health Co., Ltd. — Series B
- Shimadzu Corporation — Series B